French drugmaker Sanofi has settled a lawsuit over patents for Lantus SoloStar, its once-daily insulin in an injector-device, allowing partners Eli Lilly and Boehringer Ingelheim to sell their version in the U.S. starting December 2016.
Eli Lilly and Boehringer Ingelheim obtained tentative FDA approval in August 2014 for their version -- Basaglar in their Kwikpen device -- pending the outcome of the ongoing lawsuit.
Per the settlement, Lilly will pay undisclosed royalties to Sanofi in exchange for a license to the Sanofi patents that would have kept Basaglar off the U.S. market until April 2025.
Read the SF Gate article